Concord Medical Services Holdings (Concord Medical Services Holdings) EV-to-Revenue : 13.56 (As of May. 11, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Concord Medical Services Holdings EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Concord Medical Services Holdings's enterprise value is $1,018.78 Mil. Concord Medical Services Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $75.15 Mil. Therefore, Concord Medical Services Holdings's EV-to-Revenue for today is 13.56.

The historical rank and industry rank for Concord Medical Services Holdings's EV-to-Revenue or its related term are showing as below:

CCM' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.83 Med: 7.22 Max: 28.43
Current: 13.56

During the past 13 years, the highest EV-to-Revenue of Concord Medical Services Holdings was 28.43. The lowest was 2.83. And the median was 7.22.

CCM's EV-to-Revenue is ranked worse than
92.6% of 662 companies
in the Healthcare Providers & Services industry
Industry Median: 1.89 vs CCM: 13.56

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-11), Concord Medical Services Holdings's stock price is $0.5411. Concord Medical Services Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.72. Therefore, Concord Medical Services Holdings's PS Ratio for today is 0.31.

Concord Medical Services Holdings EV-to-Revenue Historical Data

The historical data trend for Concord Medical Services Holdings's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Medical Services Holdings EV-to-Revenue Chart

Concord Medical Services Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

23.20

26.28

14.91

15.80

13.86

Concord Medical Services Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															14.91	-	15.80	-	13.86

Competitive Comparison of Concord Medical Services Holdings's EV-to-Revenue

For the Medical Care Facilities subindustry, Concord Medical Services Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Concord Medical Services Holdings's EV-to-Revenue Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Concord Medical Services Holdings's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Concord Medical Services Holdings's EV-to-Revenue falls into.

Concord Medical Services Holdings EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Concord Medical Services Holdings's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	1018.775	/	75.147
	=	13.56

Concord Medical Services Holdings's current Enterprise Value is $1,018.78 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Concord Medical Services Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $75.15 Mil.

Concord Medical Services Holdings (NYSE:CCM) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Concord Medical Services Holdings's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.5411	/	1.72
	=	0.31

Concord Medical Services Holdings's share price for today is $0.5411.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was $1.72.

Concord Medical Services Holdings EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Concord Medical Services Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Concord Medical Services Holdings (Concord Medical Services Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Concord Medical Services Holdings Ltd (NYSE:CCM) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Room 2701-05 , 36 North Third Ring Road, Tower A, Global Trade Center, Dongcheng District, Beijing, CHN, 100013

Website

https://ir.ccm.cn

Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company operates cooperative centers across several provinces and administrative regions in China. Its network includes radiotherapy centers and diagnostic imaging centers and centers providing other treatment and diagnostic services, such as electroencephalography for the diagnosis of epilepsy, thermotherapy to increase the efficacy of and for pain relief after radiotherapy and chemotherapy, high intensity focused ultrasound therapy for the treatment of cancer, stereotactic radiofrequency ablation for the treatment of Parkinson's Disease and refraction and tonometry for the diagnosis of ophthalmic conditions.